Abstract
Meningiomas are the most common intracranial tumor, making up more than a third of all primary central nervous system (CNS) tumors. They are mostly benign tumors that can be observed or preferentially treated with gross total resection that provides good outcomes. Meningiomas with complicated histology or in compromising locations has proved to be a challenge in treating and predicting prognostic outcomes. Advances in genomics and molecular characteristics of meningiomas have uncovered potential use for more accurate grading and prediction of prognosis and recurrence. With the study and detection of genomic aberrancies, specific biologic targets are now being trialed for possible management of meningiomas that are not responsive to standard surgery and radiotherapy treatment. This review summarizes current epidemiology, etiology, molecular characteristics, diagnosis, treatments, and current treatment trials.
Highlights
Meningiomas are the most common primary central nervous system (CNS) tumors [1].They are usually benign, slow growing neoplasms that are thought to arise from meningothelial cells (MECs) [1,2,3]
Meningiomas are mostly benign tumors originating from meningothelial (arachnoid) cells (MECs), which make up
Meningiomas are more common in females and the incidence rate increases with age
Summary
Meningiomas are the most common primary central nervous system (CNS) tumors [1]. They are usually benign, slow growing neoplasms that are thought to arise from meningothelial (arachnoid) cells (MECs) [1,2,3]. Despite having a reputation of a benign disease, these dural-based tumors can lead to morbidity, presenting with a variety of non-specific, location dependent symptoms. This review discusses the recent 2016 updates to the World Health. Organization (WHO) classification of CNS tumors, epidemiology, and etiological/risk factors of meningiomas. This review covers molecular characteristics and potential applications for grading, clinical features, diagnostics, standard treatment regimens, and ongoing trials of potential treatments.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
